Greater China News
Gracell Biotechnologies to Participate in Truist Securities Cell Therapy Symposium
SAN DIEGO and SUZHOU and SHANGHAI, China, June 20, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for the treatment of cancer and autoimmune diseases, today announced that the management team will participate and host investor meetings in the Truist Securities Cell Therapy Symposium: Symposia-cel on June 27, 2023, in New York, NY.
To ease cancer drug shortage, FDA will allow imports from China
The Food and Drug Administration is working with a Chinese drugmaker to import the chemotherapy drug cisplatin, a strategy aimed at ramping up supply amid an ongoing shortage of the drug in the United States.
After Singapore, US approves sale of lab-grown meat
Two companies, Upside Foods and Good Meat, have announced that they have received the final approval from the US Department of Agriculture to sell lab-grown meat, clearing the path for the first-ever sales of the product in the United States.
Ascletis Announces Poster Presentation of Phase II Study of ASC42 FXR Agonist for Functional Cure of Chronic Hepatitis B at EASL CONGRESS 2023
HANGZHOU and SHAOXING, China, June 25, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672, "Ascletis") today announces the poster presentation of ASC42, a novel farnesoid X receptor (FXR) agonist, in combination with PEGylated interferon (PEG-IFN) and entecavir (ETV) in chronic hepatitis B (CHB) patients with 12-week treatment at European Association for the Study of the Liver (EASL) CONGRESS 2023. The s
Adicon Holdings Ltd., a Chinese diagnostic lab, announced it will raise $52.3 million by issuing 33.2 million shares via a global offering, with shares priced at $1.57 each. Read more here.
Chinese diagnostic lab company Adicon Holdings Ltd. on Monday said it will raise HK$408.9 Million ($52.29 million) via a global offering through the issuing of 33.2 million shares.
Syngenta Wins Exchange Approval for $9.1 Billion Shanghai IPO
Syngenta Group won approval from the Shanghai stock exchange for its 65 billion yuan ($9.1 billion) initial public offering, moving the world’s biggest potential listing this year a step closer to completion.
AbbVie Says BeiGene’s Flagship Blood Cancer Drug Infringes Imbruvica Patent
BeiGene Ltd (NASDAQ: BGNE) says it is aware that Pharmacyclics LLC has filed a complaint alleging that BeiGene's blood cancer therapy Brukinsa (zanubrutinib) infringes a Pharmacyclics patent issued on June 13, 2023. Pharmacyclics is an AbbVie Inc (NYSE: ABBV) company.
China imposes limits on Russian banks
The recent visit of US Secretary of State Anthony Blinken to China and the Bank of China's subsequent decision to restrict Russian bank clients’ transactions involving banks located in the EU, the United States, Switzerland and the UK, could be a coincidence.
Minghui Pharmaceutical Inc. Announces First Patient Dosing in Phase 1 Clinical Studies of Both the Antibody-Drug Conjugate Programs Targeting TROP-2 or B7-H3 Respectively, for Treatment of Advanced or Metastatic Solid Tumors
SHANGHAI and HANGZHOU, China and WILMINGTON, Del., June 20, 2023 /PRNewswire/ -- Minghui Pharmaceutical, Inc., a leading clinical-stage biopharmaceutical company, announced today that the first dosing has been completed in two phase 1 clinical studies evaluating MHB036C and MHB088C.
Jadeite Medicines Receives Orphan Drug Designation for Odevixibat in Progressive Familial Intrahepatic Cholestasis (PFIC) from the Ministry of Health, Labour and Welfare of Japan and will also initiate Phase 3 Trial of Odevixibat in PFIC in Japan
TOKYO, June 20, 2023 /PRNewswire/ -- Jadeite Medicines Inc., (Jadeite Medicines) a clinical stage biopharmaceutical company headquartered in Tokyo, Japan (President & CEO, Eiichi Takahashi) has received Orphan Drug Designation for odevixibat for the expected indication of PFIC from the Ministry of Health, Labour and Welfare (MHLW) of Japan.
